The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease.

Ralph M L Neijenhuis,Marieke Nederend,Monique R M Jongbloed,Philippine Kiès,Joris I Rotmans,Hubert W Vliegen,J Wouter Jukema,Anastasia D Egorova

Frontiers in cardiovascular medicine（2023）

引用 1|浏览3

暂无评分

摘要

Dapagliflozin was well-tolerated in this small cohort of sRV failure patients. While the early results on the reduction of NT-proBNP and clinical outcome parameters are encouraging, large-scale prospective studies are warranted to thoroughly evaluate the effects of SGLT2i in the growing sRV failure population.

查看译文

关键词

congenital heart disease, adult congenital heart disease (ACHD), heart failure, systemic right ventricle, sodium glucose co-transport-2 (SGLT2) inhibitors, transposition of the great arteries (TGA), congenitally corrected transpoition of the great arteries

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要